drugset
drugset / Trial / NCT02463448

Autologous Muscle Derived Cells for Underactive Bladder

NCT02463448 ↗

Phase 1 Completed 23 enrolled Jason Gilleran
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, open-label, Phase 1, single center study evaluating the safety and efficacy of Autologous Muscle Derived Cells as a treatment for chronic Underactive Bladder.

Timeline

Start
2016-11-16
Primary completion
2019-12
Completion
2020-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous Muscle Derived Cells Cell therapy — Other

Indications

No indication recorded.